Proteome Comparisons between Pre-Chemotherapy and Post-Chemotherapy Serum of Metastatic Osteosarcoma Patients Reveals Potential Novel Biomarker

Abstract

Osteosarcoma (OS), also known as osteogenic sarcoma, is the most common type of cancer that develops in bone. Most osteosarcoma occurs in children and young adults between the ages of 10 to 30 [1]. It accounts about 10% of childhood cancer. This cancerous (malignant) bone tumor usually develops during the period of rapid growth of an adolescence maturing into an adult. The malignant bone tumour tends to develop in the bones of the tibia (shin), femur (thigh) and humerus (upper arm).

Mass Spectrometric-Based Proteomics for Biomarker Discovery in Osteosarcoma: Current Status and Future Direction

“…Ab-Rahim et al compare serum proteomes of healthy controls to pre- or post-chemotherapy serum of metastatic osteosarcoma patients and pre-chemotherapy vs. post-chemotherapy using iTRAQ analysis [ 50 ]. Consistent with the results from Jin et al, gelsolin was downregulated in pre-chemotherapy serum compared to controls.…”